VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.

Industry

Biotechnology

Sector

Healthcare

Headquarters

US

CEO

Shawn K. Singh

Listed since

Jun 21, 2011

Employees

41

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.

Industry

Biotechnology

Sector

Healthcare

Headquarters

US

CEO

Shawn K. Singh

Listed since

Jun 21, 2011

Employees

41